Duane Nash

Duane Nash (chief executive) discloses dealings in 2 companies, chiefly Akebia Therapeutics, Inc. and Immunic, Inc. In total, 36 filings cover trades dated from 8 October 2014 to 13 June 2025.

Market trades split into 6 purchases (€126k) and 20 sales (€511k). The net balance comes to €385k on the selling side. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 8 share grants and 1 option exercise. So far in 2025, the count stands at 1 purchase and no sales.

A typical purchase (the median) is worth €13k. 4 out of 5 purchases came within 30 days of a purchase by at least one other insider of the same company. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

The record was last updated on 16 June 2025 with an open-market purchase (€14k) in Immunic, Inc. Typically, a trade is published a median of 3 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.